1. Home
  2. TRNO vs NUVL Comparison

TRNO vs NUVL Comparison

Compare TRNO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terreno Realty Corporation

TRNO

Terreno Realty Corporation

HOLD

Current Price

$60.52

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$104.39

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNO
NUVL
Founded
2009
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
7.1B
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
TRNO
NUVL
Price
$60.52
$104.39
Analyst Decision
Buy
Strong Buy
Analyst Count
12
14
Target Price
$65.08
$134.29
AVG Volume (30 Days)
642.0K
828.0K
Earning Date
02-04-2026
10-30-2025
Dividend Yield
3.39%
N/A
EPS Growth
75.67
N/A
EPS
3.15
N/A
Revenue
$442,611,000.00
N/A
Revenue This Year
$22.90
N/A
Revenue Next Year
$10.30
N/A
P/E Ratio
$19.50
N/A
Revenue Growth
21.13
N/A
52 Week Low
$48.18
$55.54
52 Week High
$69.20
$112.88

Technical Indicators

Market Signals
Indicator
TRNO
NUVL
Relative Strength Index (RSI) 44.97 51.87
Support Level $59.55 $103.52
Resistance Level $62.97 $107.99
Average True Range (ATR) 1.21 3.18
MACD -0.24 -0.93
Stochastic Oscillator 23.63 10.43

Price Performance

Historical Comparison
TRNO
NUVL

About TRNO Terreno Realty Corporation

Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: